AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05598996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COT-Based Intervention
Description: The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
Study NCT04922021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
Study NCT05603910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules taken daily by mouth
Study NCT05603910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
Study NCT05603910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated External Beam Radiation Therapy
Description: HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
Study NCT04800835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Balloon
Description: implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
Study NCT06532552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACl
Description: Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.
Study NCT06532552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACh
Description: Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
Study NCT06402227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamified instruction
Description: At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win.
Study NCT06402227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional lesson lecture
Description: The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of the speed of Nystagmus
Description: A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
Study NCT05162040 — intervention group
Intervention type: DEVICE
Intervention: Use of PedaleoVR
Description: All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application.
Study NCT04518943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of the speed of Nystagmus
Description: A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Measurement of the speed of Nystagmus
Description: A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angle of deviation at Fukuda
Description: The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Angle of deviation at Fukuda
Description: The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Angle of deviation at Fukuda
Description: The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Alexander's degree of nystagmus
Description: there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Alexander's degree of nystagmus
Description: there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left
Study NCT04678167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Alexander's degree of nystagmus
Description: there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHTEV questionnaire
Description: Handicap Scale for Balance Disorders and Vertigo
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EHTEV questionnaire
Description: Handicap Scale for Balance Disorders and Vertigo
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EHTEV questionnaire
Description: Handicap Scale for Balance Disorders and Vertigo
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEV questionnaire
Description: European Vertigo Assessment Questionnaire
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EEV questionnaire
Description: European Vertigo Assessment Questionnaire
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EEV questionnaire
Description: European Vertigo Assessment Questionnaire
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiety VAS
Description: visual analog scale of anxiety
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: anxiety VAS
Description: visual analog scale of anxiety
Study NCT04678167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: anxiety VAS
Description: visual analog scale of anxiety
Study NCT05782556 — intervention group
Intervention type: DEVICE
Intervention: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
Description: For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
Study NCT04981340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Same as previously described
Study NCT04981340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard urotherapy
Description: Same as previously described
Study NCT04981340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard urotherapy
Description: Same as previously described
Study NCT05931965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
Study NCT05931965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
Study NCT04957095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Injectable Solution
Description: Apomorphine injected for therapeutic relief
Study NCT04957095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcortical Stimulation
Description: Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
Study NCT05303272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Prefilled Syringe
Description: Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
Study NCT05303272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500Mg Tab
Description: MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
Study NCT06532552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACl Alternating With VACh
Description: VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
Study NCT05931965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
Study NCT04775758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-evaluating questionnaires
Description: Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
Study NCT04775758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-evaluating questionnaires
Description: Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
Study NCT06532552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VA
Description: Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
Study NCT05772559 — intervention group
Intervention type: OTHER
Intervention: Collection of blood sample of bone marrow (cohort 1)
Description: * 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs
Study NCT05772559 — intervention group
Intervention type: OTHER
Intervention: Collection of blood sample of bone marrow (cohort 2 and 3)
Description: * 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)
Study NCT04775758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMotions analysis platform
Description: While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
Study NCT05979129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zero PEEP
Description: zero end-expiratory pressure during face mask ventilation
Study NCT05979129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP
Description: 4 cmH2O PEEP during mask ventilation
Study NCT04775758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iMotions analysis platform
Description: While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
Study NCT05979129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high PEEP
Description: 8 cmH2O PEEP during mask ventilation
Study NCT06242496 — intervention group
Intervention type: OTHER
Intervention: Retrospective follow-up
Description: Data collection
Study NCT06342297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscopy
Description: Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
Study NCT06258993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Exercise Promotion Program
Description: Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
Study NCT06258993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core Exercise Promotion Program
Description: Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
Study NCT06258993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect-based exercise prescription
Description: Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale.
Study NCT06258993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effort-based exercise prescription
Description: Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale.
Study NCT04911114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be-Balanced
Description: The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).
Study NCT04577820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garetosmab
Description: Repeated doses administered intravenously (IV) every four weeks (Q4W)
Study NCT05484258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Medical Visit
Description: Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.